Comment from Progress Federal Solutions

Summary: Progress Federal Solutions supports the Expedited Investigational New Drug (IND) pilot program and emphasizes that the success of the initiative depends on a robust data architecture. They recommend that the FDA prioritize a platform capable of unified retrieval, semantic alignment via ontology, governed decision logic, data-layer security, and auditable defensibility to ensure actual timeline savings.